아릴기 또는 헤테로아릴기 치환된 다환의 페난트리딘 유도체 및 이를 포함한 유기 전계발광 소자
申请人:Lapto Co., Ltd. 주식회사 랩토(120120213992) Corp. No ▼ 131111-0274298BRN ▼129-86-56546
公开号:KR20170142950A
公开(公告)日:2017-12-28
하기 화학식 1의 아릴기 또는 헤테로아릴기 치환된 다환의 페난트리딘 유도체가 제공된다. [화학식 1] [상기 화학식 1에 있어서, Ar는 페닐 또는 피리딜이고, Z은 O 또는 S이고, L은 페닐 또는 피리딜이고, Ar는 하기 화학식 3으로 표시되는 군중에서 선택되는 어느 하나임] [화학식 3] , , , ,
Through the use of PdCl(dppb)(C3H5) as a catalyst, a range of aryl bromides and chlorides undergoes coupling via C-H bond activation/flunctionalization reaction with oxazole or benzoxazole in good yields. This air-stable catalyst can be used at low loadings with several substrates. Surprisingly, better results in terms of substrate/catalyst ratio were obtained in several cases using electron-excessive aryl bromides than with the electron-deficient ones. This seems to be mainly due to the relatively low thermal stability of some of the 2-arylbenzoxazoles formed with electron -deficient aryl halides. With these substrates, in order to obtain higher yields of product, the reactions had to be performed at a lower temperature (100-120 degrees C) using a larger amount of catalyst. On the other hand, in the presence of the most stable products, the reactions were performed at 150 degrees C using as little as 0.2 mol% catalyst. Arylation of benzoxazole with heteroaryl bromides also gave the coupling products in moderate to high yields using 0.2-5 mol% catalyst. With this catalyst, electron-deficient aryl chloride such as 4-chlorobenzonitrile, 4-chloroacetophenone or 2-chloronitrobenzene have also been used successfully. (c) 2007 Elsevier B.V. All rights reserved.
[EN] 4-CARBOXY PYRAZOLE DERIVATIVES AS ANTI-VIRAL AGENTS<br/>[FR] DERIVES DE 4-CARBOXY PYRAZOLE UTILISES EN TANT QU'AGENTS ANTIVIRAUX
申请人:SMITHKLINE BEECHAM CORP
公开号:WO2007039146A1
公开(公告)日:2007-04-12
[EN] Anti-viral agents of compounds of Formula (I): wherein A, R1, R2, R3 and R4 are as defined in the specification, processes for their preparation and their use in HCV treatment are provided. [FR] L'invention concerne des agents antiviraux constitués de composés de formule (I) dans laquelle A, R1, R2, R3 et R4 sont tels que définis dans la description. La présente invention se rapporte en outre à leurs procédés de préparation, et à leur utilisation pour traiter les infections par le virus de l'hépatite C (HCV).